Rep. Paul Tonko, (D-NY), and Rep. Cathy McMorris, (R-WA), debate whether President Obama or President Reagan did a better job handling the nation's economic recovery.
Related Links:
Business & financial news headlines from msnbc.com
Top of page
Source: http://video.msnbc.msn.com/cnbc/46259897/
arizona diamondbacks arizona diamondbacks alex rodriguez alicia witt alicia witt nobel peace prize verizon wireless
Communications most notably telecommunications are certainly important to any business regardless of the industry they?re included in and the size of their organisation. Being capable to talk to customers and suppliers and being a contact at the end of the line when potential customers call for additional information relating to services or existing customers have a query is very important to the successful operation of the organisation.
Although with mounting telephone bills and extortionate line rental charges many organisations have the desire to alternative approaches to the original land line telephone such as a VOIP telephone system as it can be more affordable whilst simultaneously maintaining high amounts of efficiency. A business VOIP system operates by transmitting voice communications and media over the internet as opposed to the Public Switched Telephone Network (PSTN).
The benefits of using a business VOIP system as opposed to making regular calls are that you could spend less since your telephony bills will be up to 50% lower plus you?ll receive free VoIP-to-VoIP calls, it is simply, quick and easy to set up and you can now easily maintain your existing number and that is important if individuals have come to recognise you because of your current contact number.
One more reason why businesses elect to move to Voice Over IP telephony solutions is that they will surely have one local phone number, whether they are at home in the office or outside of the UK. In effect they are able to take their telephone number with them and using a VOIP handset connect to assist them to receive and produce calls as they usually would.
Progressively more companies are attempting to save costs at the moment, particularly with the economy still moving slowly and businesses still recovering from the effects of the recession within the last few years so introducing a VOIP telephone system and spending less on their telecommunications can be just the starting point for making these savings. There is definitely room to expand with a VOIP system and having it installed by a VoIP specialist company will assure that your business makes the most of internet telephony.
To discover more about a VOIP telephone system you could stop by the Abussi website and learn more about their business VOIP system.
once upon a time once upon a time demarco murray teresa giudice red ribbon week much ado about nothing sean hayes
Spending too much time at your desk sitting (even if you do get the recommended 30 minutes a day of exercise) leads to obesity, diabetes, heart disease and even cancer. This is a bold statement, but the reality is that our bodies simply are not designed to sit for extended periods of time.
Sitting all day while we work, or more commonly called ?having a sedentary lifestyle,? has only recently become a trending topic in health and fitness, but studies of the affect of sitting while working vs. standing (and moving) while working date back to the mid-twentieth century. In an article by Maria Masters (Men?s Health) she recounts a British study published in 1953 where scientists examined two groups of workers: bus drivers and trolley conductors. The bus drivers were more likely to sit down for their entire day, the trolley conductors were running up and down the stairs and aisles trolleys. As it turned out, the bus drivers were nearly twice as likely to die of heart disease as the conductors were.
Marc Hamilton, Ph.D. from the Pennington Biomedical Research Center has labeled this area of science ?inactivity physiology.? He found that when the leg muscles are not used for a few hours, our levels of the enzyme lipoprotein lipase (LPL) drop off severely. This protein?s main role is to break down fat in the bloodstream to use as energy. He states simply, ?humans sit too much? the cure for too much sitting isn?t more exercise. Exercise is good, of course, but the average person could never do enough to counteract the effect of hours and hours of chair time.?
Increased risks of heart disease and obesity are just a couple of the health hazards related to a sedentary lifestyle. Lower back and hip pain, poor balance and mobility are also associated with prolonged periods of sitting. The list of ailments caused by too much sitting goes on to include higher risks of diabetes, depression and even cancer. Christine Friedenreich, an epidemiologist at Alberta Health Services/Cancer Care suggests that her research has found that inactivity is linked to an additional 37,000 cases of cancer. The research that has been done in the last few years on the dangers of sitting is nothing short of alarming. Sitting has become the new smoking.
The good news is that the solution is easy and quite natural ? just reduce the amount of time spent sitting. Finding additional time in a hectic work day for more exercise can seem impossible, but with the LifeSpan Treadmill Desk taking the place of an office chair, not only can you eliminate the inactivity in your workday but you will find that you will have an increase in energy as well as productivity.
Source: http://blog.lifespanfitness.com/health-risks-of-a-sedentary-lifestyle/
r kelly vanessa bryant vanessa bryant kurt busch kurt busch nfl mock draft 2012 adam lambert
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 1-Feb-2012
Share ] Contact: Catherine Meyers
cmeyers@aip.org
301-209-3088
American Institute of Physics
Incandescent light bulbs are energy hogs, but many people prefer them for the cozy quality of light they emit. Scientists from Dresden University of Technology in Germany have set out to build energy efficient organic LED (OLED) lights that could rival incandescent bulbs in white-light color quality. OLEDs consist of many layers of organic materials with different electrical properties. Excited electrons move through the materials and when the electrons are reunited with positive "holes," they emit electromagnetic radiation in the form of visible light. To build their white light OLED, the researchers used four separate emitter layers: blue, green, yellow, and red. The different colors are combined to cover all parts of the visible spectrum. Through a detailed study of the movement of electrons through the OLED, the scientists were able to tune the color and quality of the light by adjusting the height of the layers. The final OLED, described in the AIP's Journal of Applied Physics, casts a color of light very near to warm white point A, a standard measure of the white light spectrum reached by some incandescent bulbs. The OLED also has high color stability, meaning the light can be dimmed without noticeably altering its quality.
###
Article: "Organic LEDs for Lighting: High Color Quality by Controlling Energy Transfer Processes in Host-Guest-Sytems" is accepted for publication in the Journal of Applied Physics.
Authors: Caroline Weichsel (1), Sebastian Reineke (1), Mauro Furno (1), Bjrn Lssem (1), and Karl Leo (1).
(1) Institut fr Angewandte Photophysik, Technische Universitt Dresden, Germany
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 1-Feb-2012 Share ] Contact: Catherine Meyers
cmeyers@aip.org
301-209-3088
American Institute of Physics
Incandescent light bulbs are energy hogs, but many people prefer them for the cozy quality of light they emit. Scientists from Dresden University of Technology in Germany have set out to build energy efficient organic LED (OLED) lights that could rival incandescent bulbs in white-light color quality. OLEDs consist of many layers of organic materials with different electrical properties. Excited electrons move through the materials and when the electrons are reunited with positive "holes," they emit electromagnetic radiation in the form of visible light. To build their white light OLED, the researchers used four separate emitter layers: blue, green, yellow, and red. The different colors are combined to cover all parts of the visible spectrum. Through a detailed study of the movement of electrons through the OLED, the scientists were able to tune the color and quality of the light by adjusting the height of the layers. The final OLED, described in the AIP's Journal of Applied Physics, casts a color of light very near to warm white point A, a standard measure of the white light spectrum reached by some incandescent bulbs. The OLED also has high color stability, meaning the light can be dimmed without noticeably altering its quality.
###
Article: "Organic LEDs for Lighting: High Color Quality by Controlling Energy Transfer Processes in Host-Guest-Sytems" is accepted for publication in the Journal of Applied Physics.
Authors: Caroline Weichsel (1), Sebastian Reineke (1), Mauro Furno (1), Bjrn Lssem (1), and Karl Leo (1).
(1) Institut fr Angewandte Photophysik, Technische Universitt Dresden, Germany
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-02/aiop-bab020112.php
kelly cutrone bill buckner dancing with the stars 2011 christmas island antonio gates antonio gates challah
Amazon announces Q4 2011 results: sales jump to $17.43 billion, but profits drop 58 percent originally appeared on Engadget on Tue, 31 Jan 2012 16:26:00 EDT. Please see our terms for use of feeds.
Permalink |
Amazon | Email this | Comments
Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/9mWIk6jvHd0/
the darkest hour neverland marlins marlins wormwood bcs bowl games phoebe prince
Please Note this is just an outline of a sample course and I am not selling or promoting anything. I am simply frustrated by the lack of straight forward, simple to understand real estate investing courses.I was so frustrated that I took some time on my yearly vacation to design an eight-hour program that is aimed toward new real estate investors.? I wanted it to be aimed at new investors and help them get on a path to successful real estate investing.Let me know what you think.Section 1: Establish CredibilityOut of the gate, you need to establish the goals of the program, review the instructors history (both pre-crash and post-crash), and discuss what kind of deals they are doing today.? No fact real estate instructors, if they are not doing deals today then they can?t teach today?s students (my opinion).Section 2: Discuss New Investor Challenges in Today?s MarketToday?s investing market is full of opportunities.? Both success and failure can be had in this market with an investor?s first transaction.Section 3: HomeworkThe greatest folly in most of the real estate investing courses I have reviewed is that they try to make real estate investing seem as simple as flipping burgers. Let me be very clear: this business is hard and it takes work. If you don?t have the extra time and commitment, don?t even bother; you can invest passively instead of actively.I believe that homework is such a critical and overlooked part of the business for new investors that I designed a four-week program with specific goals and activities that should occur every week. The goal is to complete the activities in four weeks, but if they take six or even eight weeks, you will still be light years ahead of most new investors.Section 4: Investing while holding a Full Time JobAs a full time employee and active real estate investor, I know how hard it is to keep on top of all the moving parts in this business.I will also discuss our most important metric for evaluating deals.? This one metric allows us to compare investment properties, regardless of condition or type of property.? I will share the specific spreadsheet I use to evaluate deals and discuss the minimum threshold for a deal to be considered.Section 5: Discuss Difference between Active and Passive Real Estate InvestingToday?s real estate market offers tremendous returns for investors willing to leverage the depressed market conditions.? However, unlike most of the real estate material and books state, you don?t have to be an active real estate investor.? Many people simply don?t have the time or live in a market that doesn?t offer decent returns, and they need to know they have options.? Active Real Estate investing may sell lots of programs, but many people would prefer the options of passive investing.Section 6: Bonus MaterialIn order to exceed expectations, I would offer the following material for review:We would start by reviewing all of our deals over the last 24 months.? We would discuss our expectations going in, the actual results, and review our lessons learned.We would close the course by highlighting what we expect of the investor and what we hoped they learned after spending time with our material.
Read the full post here?
elf on a shelf elf on a shelf carrier iq carrier iq linda perry world aids day horse slaughter
Public release date: 31-Jan-2012 Share ] Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
New York, NY -- Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors. Called tryptophan 2,3-dioxygenase or TDO, the enzyme works by depriving immune cells of tryptophan, an amino acid essential to their activity. TDO is produced by a significant number of human tumors. Scientists also show that blocking TDO activity with a novel TDO inhibitor promotes tumor rejection in mice. The study findings were published online today in the January 30 issue of the Proceedings of the National Academy of Sciences (PNAS).
Cancer immunotherapy leveraging the body's own immune system to attack and destroy tumors is emerging as a promising method for cancer treatment. Clinical testing of several immunotherapeutic approaches has shown variable success. Tumors often develop survival mechanisms to prevent the attack from the immune system. Researchers are now looking to evaluate the mechanisms that enable these tumors to escape detection by the immune system.
Previously, Brussels scientists from LICR and the de Duve Institute at the Universit catholique de Louvain (UCL) studied one enzyme that proved to do just that. It is known as indoleamine 2,3 dioxygenase or IDO1 for short. IDO1 is expressed in many cancers, including prostate, colon, pancreas and cervical tumors. IDO1 blocks the immune system's ability to reject those tumors, by depriving immune cells of tryptophan. In the PNAS study released today, the same Belgian researchers have shown that TDO is also expressed in various human tumors and degrades tryptophan in a similar manner. Tumors expressing TDO include bladder and liver cancers, as well as melanomas.
"Little is known about the TDO enzyme and its ability to trick the immune system and prevent it from destroying deadly tumors. Our research is the first to explore this relationship," said study lead investigator, Benoit J. Van den Eynde, M.D., Ph.D., Brussels Branch Director at LICR.
The group studied a series of 104 human tumor lines of different types to confirm the activity of TDO in tumor cells. They learned that 20 tumors expressed TDO only, 17 others expressed IDO1 only and 16 expressed both. The findings suggest that TDO and IDO1 enzymes represent complementary cancer immunotherapy targets, which if blocked could potentially impact 51% of all tumors.
Demonstrating TDO Expression and Its Role in Thwarting Immune Attack
Using a validated mouse tumor model, researchers established that TDO expression caused tumor cells to resist immune rejection. They first vaccinated the mice with an antigen that caused them to reject the tumor. Then they injected TDO-expressing tumor cells into the immunized mice. Researchers found that immunized mice no longer rejected the TDO-expressing tumors. This demonstrated that the presence of TDO prevented the immune system from attacking tumors.
In collaboration with scientists from the University of Namur (Belgium), the team then developed an active compound to inhibit TDO enzymatic activity. "Our study showed quite beautifully that the TDO inhibitor restored the ability of mice to reject tumors despite the presence of TDO in tumor cells," said Dr. Van den Eynde.
Research recently published in the October 6, 2011 issue of Nature (Opitz, C.A. et al.) validates today's study results by showing that TDO expression in human glioblastomas promotes tumor progression.
Toward Clinical Development of a TDO-inhibitor
The research team is moving forward to validate TDO inhibition in other preclinical models. Working closely with LICR colleagues in San Diego, the team will also conduct high-throughput screening to find a more stable TDO-inhibitor compound that can be advanced in clinical testing.
LICR plans, conducts, administers, and sponsors its own clinical trials as part of its technology development process. This process allows basic investigations to continue into early stage clinical evaluation of a new therapy, and makes the clinic an essential arm of the research enterprise.
"We will continue to search for inhibitors of TDO, an important new clinical target," confirmed Jonathan Skipper, Ph.D., Executive Director, Technology Development at LICR. "LICR intends to license its discovery to a new commercial enterprise in the near future."
###
About The Ludwig Institute for Cancer Research
LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research.
For further information please contact Rachel Steinhardt, rsteinhardt@licr.org or 212-450-1582.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 31-Jan-2012 Share ] Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
New York, NY -- Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors. Called tryptophan 2,3-dioxygenase or TDO, the enzyme works by depriving immune cells of tryptophan, an amino acid essential to their activity. TDO is produced by a significant number of human tumors. Scientists also show that blocking TDO activity with a novel TDO inhibitor promotes tumor rejection in mice. The study findings were published online today in the January 30 issue of the Proceedings of the National Academy of Sciences (PNAS).
Cancer immunotherapy leveraging the body's own immune system to attack and destroy tumors is emerging as a promising method for cancer treatment. Clinical testing of several immunotherapeutic approaches has shown variable success. Tumors often develop survival mechanisms to prevent the attack from the immune system. Researchers are now looking to evaluate the mechanisms that enable these tumors to escape detection by the immune system.
Previously, Brussels scientists from LICR and the de Duve Institute at the Universit catholique de Louvain (UCL) studied one enzyme that proved to do just that. It is known as indoleamine 2,3 dioxygenase or IDO1 for short. IDO1 is expressed in many cancers, including prostate, colon, pancreas and cervical tumors. IDO1 blocks the immune system's ability to reject those tumors, by depriving immune cells of tryptophan. In the PNAS study released today, the same Belgian researchers have shown that TDO is also expressed in various human tumors and degrades tryptophan in a similar manner. Tumors expressing TDO include bladder and liver cancers, as well as melanomas.
"Little is known about the TDO enzyme and its ability to trick the immune system and prevent it from destroying deadly tumors. Our research is the first to explore this relationship," said study lead investigator, Benoit J. Van den Eynde, M.D., Ph.D., Brussels Branch Director at LICR.
The group studied a series of 104 human tumor lines of different types to confirm the activity of TDO in tumor cells. They learned that 20 tumors expressed TDO only, 17 others expressed IDO1 only and 16 expressed both. The findings suggest that TDO and IDO1 enzymes represent complementary cancer immunotherapy targets, which if blocked could potentially impact 51% of all tumors.
Demonstrating TDO Expression and Its Role in Thwarting Immune Attack
Using a validated mouse tumor model, researchers established that TDO expression caused tumor cells to resist immune rejection. They first vaccinated the mice with an antigen that caused them to reject the tumor. Then they injected TDO-expressing tumor cells into the immunized mice. Researchers found that immunized mice no longer rejected the TDO-expressing tumors. This demonstrated that the presence of TDO prevented the immune system from attacking tumors.
In collaboration with scientists from the University of Namur (Belgium), the team then developed an active compound to inhibit TDO enzymatic activity. "Our study showed quite beautifully that the TDO inhibitor restored the ability of mice to reject tumors despite the presence of TDO in tumor cells," said Dr. Van den Eynde.
Research recently published in the October 6, 2011 issue of Nature (Opitz, C.A. et al.) validates today's study results by showing that TDO expression in human glioblastomas promotes tumor progression.
Toward Clinical Development of a TDO-inhibitor
The research team is moving forward to validate TDO inhibition in other preclinical models. Working closely with LICR colleagues in San Diego, the team will also conduct high-throughput screening to find a more stable TDO-inhibitor compound that can be advanced in clinical testing.
LICR plans, conducts, administers, and sponsors its own clinical trials as part of its technology development process. This process allows basic investigations to continue into early stage clinical evaluation of a new therapy, and makes the clinic an essential arm of the research enterprise.
"We will continue to search for inhibitors of TDO, an important new clinical target," confirmed Jonathan Skipper, Ph.D., Executive Director, Technology Development at LICR. "LICR intends to license its discovery to a new commercial enterprise in the near future."
###
About The Ludwig Institute for Cancer Research
LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research.
For further information please contact Rachel Steinhardt, rsteinhardt@licr.org or 212-450-1582.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-01/lifc-ntf013112.php
trans siberian orchestra trans siberian orchestra little big town little big town bennett bennett daniel day lewis
